Quick Answer
Kymera Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $39.21 million for the year ending 2025.
- Kymera Therapeutics, Inc. showed a decrease of -16.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,236.4%.
- Historical annual values: Fiscal year 2025: $39.21 million | Fiscal year 2024: $47.07 million | Fiscal year 2023: $78.59 million | Fiscal year 2022: $46.83 million | Fiscal year 2021: $72.83 million | Fiscal year 2020: $34.03 million | Fiscal year 2019: $2.93 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: